About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer

~ Appointment Strengthens Clinical Leadership as VectorY Prepares to Submit Investigational New Drug Application for VTx-002 in Sporadic ALS by Year-End 2025 ~

VectorY Therapeutics, a biotechnology company advancing vectorized antibody therapies for neurodegenerative diseases, today announced the appointment of Olga Uspenskaya-Cadoz, M.D., Ph.D., as Chief Medical Officer (CMO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401382454/en/

Dr. Olga Uspenskaya-Cadoz, the new Chief Medical Officer to VectorY Therapeutics

Dr. Olga Uspenskaya-Cadoz, the new Chief Medical Officer to VectorY Therapeutics

Dr. Uspenskaya-Cadoz brings two decades of experience in neurology, gene therapy, and clinical development, enhancing VectorY’s leadership in developing transformative treatments for neurodegenerative conditions. Her appointment comes as the company prepares to submit an investigational new drug (IND) application for its lead candidate, VTx-002, for sporadic amyotrophic lateral sclerosis (ALS) before the end of 2025 and enter clinical development in 2026.

Dr. Uspenskaya-Cadoz joins VectorY from Eli Lilly, where she served as Vice President, Medical, Gene Therapy. In this role, she led clinical development, clinical operations, pharmacovigilance and patient advocacy for central nervous system (CNS) and lysosomal storage genetic medicines. She also was an integral part of the company’s ALS and rare disease strategy team. Prior to Eli Lilly, she served as Vice President of Clinical Development at Prevail Therapeutics, where she played a pivotal role in designing clinical programs for novel gene therapies targeting neurodegenerative disorders.

With a career spanning global biopharmaceutical companies and leading academic institutions, Dr. Uspenskaya-Cadoz has extensive expertise in neurology, neurodegeneration, and translational medicine. She has contributed to large-scale clinical trials in Alzheimer’s disease, ALS, and other CNS disorders at IQVIA, Quintiles, and the University Hospital Pitié-Salpêtrière. She also has a strong research background, having conducted studies on neurochemical biomarkers and neuroimaging in Alzheimer’s disease.

“On behalf of the VectorY team, we welcome Olga at this important stage of our growth,” said Jim Scibetta, chief executive officer of VectorY Therapeutics. “Her deep expertise in neurology and gene therapy, combined with her leadership in clinical development, will be invaluable as we advance our pipeline of vectorized antibody therapies targeting neurodegenerative diseases. With the planned submission of an IND for VTx-002 in sporadic ALS before the end of 2025 and initiation of clinical development in 2026, her leadership will be instrumental in guiding the program toward success.”

Dr. Uspenskaya-Cadoz earned her M.D. and Ph.D. in Neurosciences from First Moscow State Medical University, with additional research training at Ludwig-Maximilians University in Munich and the Sorbonne University of Paris. She has authored more than 20 peer-reviewed publications and contributed to multiple book chapters on neurodegenerative diseases. In addition, she has presented extensively at international conferences and remains actively engaged in the scientific community, shaping the discourse on novel therapeutic approaches for neurodegenerative disorders.

“I am very pleased to join VectorY and contribute to its mission of developing innovative therapies for patients with neurodegenerative diseases,” said Dr. Uspenskaya-Cadoz. “Vectorized antibody approaches have the potential to revolutionize treatment paradigms, and I look forward to working with the team to advance these promising programs.”

About VectorY Therapeutics

VectorY is on a mission to provide patients with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS. For more information, visit www.VectorYtx.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.